StreetAlpha.app
Home › Stocks › OPRX

OptimizeRx Corp (OPRX)

$6.94
▲ +4.52%
LAST CLOSE · NOV 17

OptimizeRx provides digital marketing and audience targeting technology that helps life sciences brands reach healthcare providers and patients. It last closed at $6.94 on Nov 17, up 4.52% on the day. OPRX last reported earnings on Wed, Nov 11, 2026. The average 12-month price target from 3 analysts is $10.50 (+51.3% from the last close), with a high of $11.00 and a low of $10.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).

AI Auto Pilots
Is OPRX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$94.2M
−14.0% vs a year ago
Net income
$5.0M
+14655.9% vs a year ago
EPS (diluted)
$0.26
+2500.0% vs a year ago
Free cash flow
$19.9M
21.1% margin
Valuation
Market cap
$131.2M
18.9M shares
P/E
26.7
Price over 12 month EPS
Price to sales
1.4
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$22.3M
At Sep 30
Debt
$13.4M
At Sep 30
Shareholder equity
$133.9M
Shares outstanding
18.9M
At Oct 29
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $61.3M$61.3MFY2021FY2022: $62.5M$62.5MFY2022FY2023: $71.5M$71.5MFY2023FY2024: $92.1M$92.1MFY2024FY2025: $109.4M$109.4MFY2025

From OPRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.

Last report
Nov 11
2026 · After the close (AMC)
Reported EPS
$0.13
vs $0.07 est. · beat
Year-ago EPS
—
Not on file
Options-implied move
±16.9%
Priced in before that report
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on OPRX in the past 90 days
Average 12-month target
$10.50
▲ 51.3% upside

Based on 3 analysts who set a price target on OPRX in the past 90 days. The average target is $10.50, with a high of $11.00 and a low of $10.00, compared with the last close of $6.94.

Low $10.00Avg $10.50High $11.00
Blue marker: last close $6.94
Highest target$11.00
Average target$10.50
Lowest target$10.00
Latest rating changes
Lake StreetMaintained
Nov 12Buy$10
B. Riley SecuritiesReiterated
Nov 12Buy$10.50
StifelMaintained
Nov 12Buy$11
CitizensMaintained
Aug 14Buy$11
DateFirmActionRatingPrice target
Nov 12Lake StreetMaintainedBuy$10
Nov 12B. Riley SecuritiesReiteratedBuy$10.50
Nov 12StifelMaintainedBuy$11
Aug 14CitizensMaintainedBuy$11
Loading…

Technical Analysis

OPRX · as of the Nov 17 close · updated after every close
Turning down, nearing oversold

The stock is 28% below its 20 day and 21% below its 50 day average. It is 3% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 34), near oversold. The nearest support is the Pivot at $6.86, and the nearest resistance the Pivot R1 at $7.11.

Short trendBearish
Long trendNeutral
MomentumWeak
StretchNear oversold
VolatilityHigh, 10.3%/day
Key levels
$15.5952 week high+124.6%
$8.8520 day average+27.5%
$8.3950 day average+20.9%
$7.70100 day average+11.0%
$7.40Swing high (Aug 7)+6.6%
$7.12200 day average+2.6%
$7.11Pivot R1+2.4%
$6.94Last close
$6.86Pivot−1.2%
$6.86Swing low (Sep 10)−1.2%
$6.69Pivot S1−3.6%
$4.5452 week low−34.6%
Indicators
RSI (14)33.68Weak, oversold below 30Neutral
MACD-0.28Below its signal lineBearish
Stochastic13.6Near the bottom of its rangeOversold
ADX (14)28.1Trending down
Williams %R-87.4Oversold below −80, overbought above −20Oversold
CCI (20)-218.9Oversold below −100, overbought above 100Oversold
Rate of change−25.6%Change over 10 sessionsBearish
ATR (14)$0.71Typical daily range, 10.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for OPRX

What happened before

See how OPRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow OPRX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How OPRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2007.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in OPRX in the last 90 days.

Loading…

See today’s whale options flow across the market →

OPRX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ▼40 buying vs 63 selling
  • ▲Held by funds +5.3 pts
  • ▼Funds holding -10
  • ▼Superinvestors: 1 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding103113−8.8%
In funds' top 10110.0%
Held by funds64.7%59.4%+5.3 pts
New / increased13 / 2722 / 33−27.3%
Reduced / sold out38 / 2542 / 37−20.3%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See OPRX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether OPRX is in one of them and how their past OPRX trades turned out.

OPRX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered OPRX in an article yet. Here's the latest on the wider market.

About OptimizeRx

OptimizeRx is a healthcare technology company based in Waltham, Massachusetts. It sells digital marketing and engagement solutions to life sciences brands, helping them reach doctors, pharmacists and patients through electronic health record systems, prescribing platforms and consumer media channels. Its offerings include audience targeting tools, pharmacy stock alerts and copay offer information shown to prescribers at the point of care. Its customers are drug manufacturers and their agency partners.

Headquarters
Waltham, MA